Format

Send to

Choose Destination
Rev Neurol (Paris). 2013 Oct;169(10):719-23. doi: 10.1016/j.neurol.2013.07.012. Epub 2013 Sep 7.

Biomarkers of Alzheimer's disease: the present and the future.

Author information

1
Laboratoire de biochimie protéomique clinique et CCBHM, hôpital Saint-Éloi, institut de recherche en biothérapie, CHU de Montpellier, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France; Inserm U1040, université Montpellier 1, 80, avenue A.-Fliche, 34295 Montpellier cedex 5, France. Electronic address: s-lehmann@chu-montpellier.fr.

Abstract

A paradigm shift has occurred in the last ten years in the diagnostic field of Alzheimer's disease (AD). Scientific thought has enriched the concept of AD as a pathophysiological continuum and emphasized contribution of biological, morphological and functional brain imaging biomarkers for diagnosis, in particular during the early stages of the disease. We address here the present and the future of these biological biomarkers. Most of them are linked to the pathophysiological lesions of the Alzheimer process: aggregates of hyperphosphorylated tau proteins, also called neurofibrillary tangles (NFT), and extracellular deposit of amyloid-beta peptides (Aβ), also called senile plaques. The detection in the cerebrospinal fluid (CSF) of tau and Aβ represents the current diagnostic practice of AD. Improvement for a more accurate and earlier biological diagnosis is however expected using a new generation of biomarkers, mostly in relation with tau and Aβ metabolism.

KEYWORDS:

Alzheimer; Alzheimer's disease; Biomarkers; Biomarqueurs; Diagnosis; Diagnostic; Peptides amyloïdes; Protéine Tau; Tau protein; β-amyloid peptides

PMID:
24021316
DOI:
10.1016/j.neurol.2013.07.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center